AcuCort

– The launch is proceeding exactly as planned, and we have thus achieved yet another important milestone. Physicians can prescribe Zeqmelit®, and the product is now available at Swedish pharmacies. It will soon also be available at pharmacies in Norway and Finland, says AcuCort's CEO, Jonas Jönmark. 

For further information: 
Jonas Jönmark, vd, AcuCort AB
Tel: +46 70 365 5400
Email: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.